Dan Schell articles

  1. From Hint To Headline: FOMAT Acquires Site Network 5/5/2026

    FOMAT Medical CEO, Nick Focil, talks about the company’s acquisition of site network Topography Health — a deal that expands FOMAT’s national footprint and reflects a broader trend of site network growth aimed at scaling access, data, and operational reach.

  2. The Industry Talks Access — Fabian Sandoval Builds It 5/1/2026

    Fabian Sandoval is redefining what a clinical research site looks like — building trust through community partnerships, media, and education to improve trial access and awareness long before enrollment begins.

  3. The Rise — And Stall — Of Retail Pharmacy Clinical Trials 4/23/2026

    As rumors swirl that Walgreens may be reassessing its clinical trials business, this article explores a broader trend: why major retail pharmacy chains like CVS, Walmart, and Kroger have struggled to make the model work at scale.

  4. Clinical Trials Have A Native American Problem 4/14/2026

    Kelsey Powell is working to close a long-standing gap in clinical trials: the lack of participation from Native American communities. Her experience highlights how issues of trust, awareness, and fragmented systems continue to limit access — and what it will take to change that.

  5. RBQM And Centralized Monitoring Need Action 4/10/2026

    After COVID forced sponsors to move faster than ever, many are now confronting a harder challenge: ownership. Marci Thear explains why RBQM and centralized monitoring only work when sponsors move beyond reviewing outputs and start acting on the signals.

  6. RWE Is Ready — Decision Making For Pharmaceuticals Isn't 4/1/2026

    Gorana Capkun of Merck, KGaA, Darmstadt, Germany discusses the growing role of real-world evidence in clinical trials, highlighting a gap between regulatory momentum and pharma adoption— and the challenge of turning data into better decisions.

  7. CROs, AI, And The New Economics Of Outsourcing 3/23/2026

    AI and automation are starting to reshape clinical trial outsourcing, but not disrupt it — yet. As CRO consultant Joel White notes, revenues remain strong as trial activity rises, with efficiency gains showing up in margins rather than reduced demand. Large site networks may erode some site-facing work, but won’t replace full-service CROs. The real shift is in how value is captured, and the key signal to watch is whether CRO revenues begin to lag behind trial activity.

  8. Wanted: More Women For Clinical Trials 3/13/2026

    A new national survey from UPMC’s Center for Connected Medicine examines why women remain underrepresented in clinical trials. The research highlights key barriers such as fear of side effects, time and travel burdens, and limited awareness about how trials work. In a conversation with UPMC’s Nicole Ansani, we explore what sites and sponsors can do to make trials more accessible and appealing to women.

  9. Do We Still Need To "Save" Our Sites? 3/11/2026

    Budget negotiations, sponsor expectations, operational pressures, and burnout all remained front-and-center concerns at this year's Save Our Sites (SOS) conference. In this recap, I share key takeaways from the sessions I attended — including practical budgeting advice, sponsor “turn-offs,” and a few unbelievable (but true) sponsor horror stories — along with why gatherings like SOS still matter for the site community.

  10. Why Africa Could Be The Next Frontier For Clinical Trials 3/6/2026

    Africa hosts only about 3% of global clinical trials despite representing roughly 20% of the world’s population. Tariro Makadzange, founder and CEO of the Africa Clinical Research Network (ACRN), explains how the organization aims to build a continent-wide clinical trial platform and increase that share to 15% over the next decade.